Sign In
Buy SLS
$8.23
-0.81 (-8.96%)
At Close: Jun 05, 2026
SELLAS Life Sciences Stock Is Surging Wednesday: What's Driving The Move?
09:41am, Wednesday, 20'th May 2026
Sellas Life Sciences Group Inc (NASDAQ:SLS) shares are trading higher on Wednesday as traders react to the company's latest update on its acute myeloid leukemia pipeline and the timeline for a pivotal
SELLAS Life Sciences to Participate in Upcoming Investor Conferences
08:00am, Thursday, 14'th May 2026
NEW YORK, May 14, 2026 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) (“SELLAS” or the “Company”), a late-stage clinical biopharmaceutical company focused on the developmen
SELLAS Life Sciences Nears Pivotal Trial Readout As Leukemia Pipeline Progresses
10:18am, Wednesday, 13'th May 2026
SELLAS Life Sciences Group Inc. (NASDAQ:SLS) reported first-quarter (Q1) 2026 financial results on Tuesday while highlighting progress across its acute myeloid leukemia (AML) pipeline.
SELLAS Life Sciences Reports First Quarter 2026 Financial Results and Provides Corporate Update
04:05pm, Tuesday, 12'th May 2026
– Contract Research Organization for the Pivotal Phase 3 REGAL Trial of Galinpepimut-S (GPS) in Acute Myeloid Leukemia (AML) Informed the Company that 78 Events have Occurred in the Trial as of May
Sellas Life Sciences: 'Hold' As Phase 3 AML Study Progresses To Key Event
03:06pm, Thursday, 23'rd Apr 2026
SELLAS Life Sciences is rated 'Hold' due to pending phase 3 REGAL data for GPS in AML after CR2, a major 2026 catalyst. The company's GPS targets WT1 in AML, with prior phase 1/2 data showing a median
Wall Street Analysts Think SELLAS Life Sciences Group, Inc. (SLS) Could Surge 66.09%: Read This Before Placing a Bet
10:56am, Monday, 20'th Apr 2026
The mean of analysts' price targets for SELLAS Life Sciences Group, Inc. (SLS) points to a 66.1% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong
All You Need to Know About SELLAS Life Sciences Group, Inc. (SLS) Rating Upgrade to Buy
01:00pm, Thursday, 26'th Mar 2026
SELLAS Life Sciences Group, Inc. (SLS) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near ter
Wall Street Analysts Believe SELLAS Life Sciences Group, Inc. (SLS) Could Rally 63.58%: Here's is How to Trade
10:56am, Thursday, 26'th Mar 2026
The consensus price target hints at a 63.6% upside potential for SELLAS Life Sciences Group, Inc. (SLS). While empirical research shows that this sought-after metric is hardly effective, an upward tre
SELLAS Life Sciences Group (NASDAQ:SLS) Shares Gap Up on Earnings Beat
01:14am, Saturday, 21'st Mar 2026
SELLAS Life Sciences Group, Inc. (NASDAQ: SLS - Get Free Report) shares gapped up before the market opened on Friday following a better than expected earnings announcement. The stock had previously cl
SELLAS Stock Up 346% in a Year as Cancer Vaccine Trial Nears Its Final 8 Deaths
08:00am, Friday, 20'th Mar 2026
A late-stage clinical biopharmaceutical company focused on immunotherapy for various cancers, SELLAS Life Sciences Group ( NASDAQ:SLS ) is at a genuinely unusual inflection point.
SELLAS Life Sciences Group (NASDAQ:SLS) & Dianthus Therapeutics (NASDAQ:DNTH) Critical Survey
01:32am, Friday, 20'th Mar 2026
SELLAS Life Sciences Group (NASDAQ: SLS - Get Free Report) and Dianthus Therapeutics (NASDAQ: DNTH - Get Free Report) are both medical companies, but which is the better business? We will contrast the
SELLAS Life Sciences Reports Full Year 2025 Financial Results and Provides Corporate Update
04:05pm, Thursday, 19'th Mar 2026
– Continued Advancement of Pivotal Phase 3 REGAL Trial of Galinpepimut-S (GPS) in Acute Myeloid Leukemia (AML) - Final Analysis upon Reaching 80 Events –
SELLAS Life Sciences to Present Preclinical Data Highlighting Potent Activity of SLS009 in AML at the 2026 AACR Conference
04:30pm, Tuesday, 17'th Mar 2026
- Preclinical data show that SLS009 lowers the apoptotic threshold in AML cells by suppressing critical survival pathways - - Preclinical data show that SLS009 lowers the apoptotic threshold in AML ce
SELLAS Life Sciences Announces Enrollment of First Patient in Newly Diagnosed First-Line AML Trial of SLS009
08:35am, Thursday, 12'th Mar 2026
- Study to Enroll 80 Patients Unlikely to Benefit from Venetoclax/Azacitide (Aza/Ven) Therapy in the US and Europe - - SELLAS' Predictive Biomarker and AI Assisted Precision Medicine Models to be Util
What's Going With SELLAS Life Sciences Stock On Wednesday?
12:59pm, Wednesday, 04'th Mar 2026
SELLAS Life Sciences Group Inc. (NASDAQ: SLS) has surged over 200% over the last six months, with a year-to-date stock jump of around 45%.
